Current Report Filing (8-k)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act
Date of Report (Date of Earliest Event Reported): December 15,
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
Employer Identification No.)
400 Oyster Point Blvd., Suite 505, South San Francisco,
(Address of principal executive offices and zip code)
(Registrant’s telephone number including area code)
(Registrant’s former name or former address, if changed since last
Securities registered pursuant to Section 12(b) of the
of each class
of each exchange on which registered
Stock, $0.001 par value
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On December 15, 2020, Titan
Pharmaceuticals, Inc. (the “Company”) received notification from
The Nasdaq Stock Market (“Nasdaq”) confirming that the Company had
regained compliance with Nasdaq’s minimum bid price requirement and
is in compliance with all applicable listing standards.
Accordingly, the scheduled hearing before the Nasdaq Hearings Panel
has been cancelled and the Company’s common stock will continue to
trade on the Nasdaq Capital Market.
9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
/s/ Kate Beebe DeVarney, Ph.D.
Name: Kate Beebe DeVarney, Ph.D.
President and Chief Operating Officer
Dated: December 16, 2020